Evaluation of the Completeness of Managed Care Data to Identify Cancer Diagnoses and Treatments for Patients in the Seer-Medicare Data
Bibliographic Data
| ID | 9098922 |
|---|---|
| Authors | Joan L Warren (0000-0002-6467-6769, National Cancer Institute/DCCPS, Bethesda, MD, corresponding author), Helen M Parsons (0000-0003-3822-9858, University of Minnesota), Helen Parsons (0000-0002-2765-3728, University of Minnesota), Angela B Mariotto (0000-0003-2423-1834, National Cancer Institute/DCCPS, Bethesda, MD, corresponding author), Eric Boyd (0009-0005-9161-6963, Information Management Services, Calverton, MD), Lindsey Enewold (0000-0003-0452-5771, National Cancer Institute/DCCPS, Bethesda, MD, corresponding author) |
| Year | 2023 |
| Volume | 61 |
| Issue | 12 |
| Pages | 846-857 |
| Publication date | 2023-12-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Medical Care (JOURNAL) |
| Journal identifiers | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/mlr.0000000000001936 |
| PMID | 37796197 |
| OpenAlex | W4387356805 |
| Language | EN |
| Citations received | 1 |
| References cited | 8 |
BACKGROUND: The utility of codes on Medicare Advantage (MA) data to capture cancer diagnoses and treatment for cancer patients is unknown. OBJECTIVE: This study compared cancer diagnoses and treatments on MA encounter data (MA data) with the Surveillance, Epidemiology, and End-Results (SEER) data. SUBJECTS: Subjects were patients enrolled in either MA or Medicare fee-for-service (MFFS) when diagnosed with incident breast, colorectal, prostate, or lung cancer, 2015-2017, in a SEER cancer registry. MEASURES: MA data, from 2 months before to 12 months following SEER diagnosis, were reviewed to identify cancer diagnoses, surgery, chemotherapy, and radiotherapy (RT). MA data were compared with SEER to determine their sensitivity to capture cancer diagnoses and sensitivity/specificity to identify surgeries. The agreement between SEER and Medicare data regarding receipt of chemotherapy and RT was measured by Kappa statistics. A similar comparison to SEER diagnoses/treatments was made using MFFS claims to provide context for the SEER-MA comparison. RESULTS: The study included 186,449 patients, 38% in MA. MA data had 92%+ sensitivity to identify SEER cancer diagnosis and 90%+ sensitivity for cancer surgery. Specificity for surgery was >84%, except for breast cancer (52%). Kappa statistics for agreement between SEER and MA data regarding chemotherapy varied by cancer, 0.61-0.82, and for receipt of RT exceeded 0.75 for all cancers. Results observed for MFFS claims were similar to those in MA data. CONCLUSION: For 4 common cancers, MA data included most cancer diagnoses and general types of cancer treatment reported in the SEER data. More research is needed to assess additional cancers and detailed treatments
Breast cancer · Cancer · Cancer registry · Lung cancer · Medical diagnosis · Radiology · Surveillance, Epidemiology, and End Results · Economic and Financial Impacts of Cancer · Epidemiology · Global Cancer Incidence and Screening · Health Systems, Economic Evaluations, Quality of Life · Internal Medicine · Medicine · Oncology
The Measurement of Observer Agreement for Categorical Data
Comparison of Seer Treatment Data With Medicare Claims
Utility of the Seer-Medicare Data to Identify Chemotherapy Use
Studying Radiation Therapy Using Seer-Medicare-Linked Data
Use of Seer-Medicare Data for Measuring Cancer Surgery
Accuracy and Completeness of Medicare Claims Data for Surgical Treatment of Breast Cancer
| Citations per year | 1 |
|---|---|
| Citation span | 2025 - 2025 (1) |
| Highly cited | No |